WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study
Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study
Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…Physical Activity in Early Parkinson Disease
Objective: To characterize physical activity habits in patients with early Parkinson disease (PD). Background: Physical activity is an important therapy for PD as it may…Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease
Objective: The purpose of this study was to determine if Docosohexanoic acid (DHA) affects the speed and severity of development of levodopa induced dyskinesia (LID) in subjects starting levodopa (LD).…Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis
Objective: To demonstrate the feasibility, reliability, and value of conducting web-based clinical trial assessments in individuals with Parkinson disease (PD). Background: Increasing interest has been…Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III
Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…Deep brain stimulation in early stage Parkinson’s disease: Is it disease modifying?
Objective: To examine patterns of motor symptom worsening in the 2 years following deep brain stimulation (DBS) in early stage Parkinson's disease (PD). Background: Although…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures
Objective: To investigate the trends in Huntington's disease (HD) therapeutic development by analyzing interventional clinical trials publicly registered for the last 15 years. Background: Like…Disease-related variables effect on depression and anxiety level in Parkinson’s patients
Objective: To evaluate correlations of depression and anxiety levels with motor symptoms, non-motor symptoms and pharmacological factors in Parkinson's disease (PD). Background: Depression and anxiety…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.